Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Phasebio Pharmaceuticals Inc (PHAS)

Phasebio Pharmaceuticals Inc (PHAS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code Business Wire - Mon Oct 24, 2022

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced...

PHAS : 0.0701 (-26.21%)
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights Business Wire - Fri Aug 12, 2022

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported...

PHAS : 0.0701 (-26.21%)
UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates Zacks - Mon Aug 8, 2022

uniQure (QURE) delivered earnings and revenue surprises of 12.50% and 97.47%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

QURE : 4.50 (-0.88%)
PHAS : 0.0701 (-26.21%)
Author
10 Penny Stocks with > 1,000% Upside TipRanks - Thu Jun 16, 2022

Rising interest rates, sky-high inflation, and geopolitical concerns have dragged down the S&P 500 (SPX) and NASDAQ Composite (NDX) into bear market territory. While all this sounds rather doom and gloom,...

AMTI : 0.2630 (-14.30%)
ANGN : 10.0000 (+2.04%)
CKPT : 1.4400 (+1.41%)
EFTR : 1.8400 (+1.66%)
FRLN : 6.48 (unch)
GLYC : 1.6800 (-1.75%)
MGNX : 14.68 (+2.16%)
OCUP : 1.5350 (+0.33%)
PHAS : 0.0701 (-26.21%)
PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates Zacks - Mon May 16, 2022

PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of 65.67% and 98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

PHAS : 0.0701 (-26.21%)
PTN : 1.7100 (-0.58%)
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights Business Wire - Mon May 16, 2022

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported...

PHAS : 0.0701 (-26.21%)
PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab Business Wire - Mon May 16, 2022

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced...

PHAS : 0.0701 (-26.21%)
PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference Business Wire - Thu Apr 7, 2022

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced...

PHAS : 0.0701 (-26.21%)
PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab Business Wire - Mon Apr 4, 2022

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced...

PHAS : 0.0701 (-26.21%)
PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights Business Wire - Thu Mar 24, 2022

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported...

PHAS : 0.0701 (-26.21%)

Barchart Exclusives

This Warren Buffett Dividend Stock is Destroying the S&P 500 in 2024 Barchart - 20 minutes ago
This standout performer in the consumer staples sector is putting the broader market to shame this year, even as it continues to offer value in a challenging economic landscape. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot